The U.S. Supreme Court on Monday declined to hear Gilead Sciences Inc's appeal of a ruling that allowed a whistleblower lawsuit alleging it defrauded the government into paying for HIV medications whose main ingredient came from an unregistered Chinese facility to move forward.